retatrutide clinical trial retatrutide VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide: What We Know About

GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential

doi: 10.1016/j.amjcard.2004.08.059 184 BuscemiSNicolucciALucisanoGGalvanoFGrossoGMassentiFMet al

Authorities strictly prevent the direct advertising of prescription medications

Recently, agonists of glucagon-like peptide-1 (GLP-1) receptor, designed based on the gut hormone GLP-1, have been developed as anti-obesity drugs and have demonstrated remarkable efficacy in treating both obesity and diabetes

Some people shouldnt take it, including people with a personal or family history of medullary thyroid cancer, or people with multiple endocrine neoplasia syndrome type 2

Ojo OA, Amanze JC, Oni AI, Grant S, Iyobhebhe M, Elebiyo TC, Rotimi D, Asogwa NT, Oyinloye BE, Ajiboye BO, Ojo AB